Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
---|---|---|---|---|
methotrexate use | ||||
ACR/EULAR 2010 criteria | 0.74 (0.65 to 0.82) | 0.66 (0.54 to 0.76) | 0.76 (0.67 to 0.83) | 0.63 (0.52 to 0.73) |
van der Helm algorithm | 0.10 (0.05 to 0.17) | 1.0 (0.95 to 1.0) | 1.0 (0.74 to 1.0) | 0.43 (0.35 to 0.50) |
Visser algorithm | 0.59 (0.50 to 0.68) | 0.93 (0.85 to 0.97) | 0.92 (0.84 to 0.97) | 0.62 (0.53 to 0.71) |
Persistent disease | ||||
ACR/EULAR 2010 criteria | 0.69 (0.61 to 0.76) | 0.72 (0.59 to 0.83) | 0.87 (0.80 to 0.92) | 0.46 (0.35 to 0.56) |
van der Helm algorithm | 0.08 (0.05 to 0.14) | 1.0 (0.93 to 1.0) | 1.0 (0.75 to 1.0) | 0.27 (0.21 to 0.34) |
Visser algorithm | 0.47 (0.39 to 0.55) | 0.93 (0.84 to 0.98) | 0.95 (0.87 to 0.99) | 0.40 (0.31 to 0.48) |
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; NPV, negative predictive value; PPV, positive predictive value, UA, undifferentiated arthritis.